Tofacitinib alters STAT3 signaling and leads to endometriosis lesion regression

Tofacitinib alters STAT3 signaling and leads to endometriosis lesion regression is a paper indexed in ScholarIQ from OpenAlex.

How many citations does Tofacitinib alters STAT3 signaling and leads to endometriosis lesion regression have?

Tofacitinib alters STAT3 signaling and leads to endometriosis lesion regression has 45 citations in the OpenAlex counts ScholarIQ stores.

When was Tofacitinib alters STAT3 signaling and leads to endometriosis lesion regression published?

Tofacitinib alters STAT3 signaling and leads to endometriosis lesion regression has 2021 year in the ScholarIQ index.

What is the open-access status of Tofacitinib alters STAT3 signaling and leads to endometriosis lesion regression?

Tofacitinib alters STAT3 signaling and leads to endometriosis lesion regression has bronze oa status in the ScholarIQ index.

What is the DOI of Tofacitinib alters STAT3 signaling and leads to endometriosis lesion regression?

The DOI for Tofacitinib alters STAT3 signaling and leads to endometriosis lesion regression is on the source record.

What is the PMID of Tofacitinib alters STAT3 signaling and leads to endometriosis lesion regression?

The PMID for Tofacitinib alters STAT3 signaling and leads to endometriosis lesion regression is on the source record.

What is the OpenAlex record for Tofacitinib alters STAT3 signaling and leads to endometriosis lesion regression?

The OpenAlex for Tofacitinib alters STAT3 signaling and leads to endometriosis lesion regression is on the source record.